HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and raises the price target from $21 to $22.
May 13, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Y-mAbs Therapeutics and increased the price target from $21 to $22.
The upgrade in price target by a reputable analyst suggests a positive outlook on the stock, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100